- Conditions
- Type 1 Diabetes, Type 2 Diabetes
- Interventions
- IIM System, Insulin Lispro and/or Insulin Glargine
- Device · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Walnut Creek, California • Austin, Texas + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 304
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
- Interventions
- Orforglipron, Insulin Glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,749 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 173
- States / cities
- Daphne, Alabama • Mobile, Alabama • Pelham, Alabama + 149 more
- Conditions
- Type 2 Diabetes
- Interventions
- LY900014, Insulin Glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 30
- States / cities
- Concord, California • Escondido, California • Fresno, California + 25 more
- Conditions
- Type 2 Diabetes
- Interventions
- Colesevelam, Colesevelam matching placebo, Insulin glargine (Lantus)
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Gestational Diabetes Mellitus, Pregnancy, High Risk
- Interventions
- Metformin, Insulin
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,572 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 26
- States / cities
- Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 20 more
- Conditions
- Diabetes Mellitus, Chronic Obstructive Pulmonary Disease
- Interventions
- Subcutaneous Insulin, Inhaled Insulin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 30 Years to 77 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 77
- States / cities
- Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 59 more
- Conditions
- Diabetes Mellitus
- Interventions
- Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L, Lispro
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Type 2 Diabetes
- Interventions
- Linagliptin, Basal Bolus, Linagliptin + 50% Glargine dose on discharge, Linagliptin + 80% Glargine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 1 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Interventions
- MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg, Glargine 0.4 U/kg, Placebo to Glargine, Placebo to MK-5160, Dextrose, Glargine 0.6 U/kg
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin degludec/liraglutide, insulin glargine
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,012 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 44
- States / cities
- Muscle Shoals, Alabama • Tuscumbia, Alabama • Glendale, Arizona + 37 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- albiglutide + insulin glargine, insulin glargine + preprandial lispro insulin
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 586 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 142
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Gilbert, Arizona + 119 more
- Conditions
- Diabetes
- Interventions
- linagliptin, insulin glargine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Decatur, Georgia
- Conditions
- Type 2 Diabetes
- Interventions
- Sitagliptin, Basal Bolus, Metformin and Sitagliptin, Glargine, Glargine 50%, Glargine 80%
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Ann Arbor, Michigan • Columbus, Ohio + 1 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- Faster-acting insulin aspart, basal insulin
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Little Rock, Arkansas + 27 more
- Conditions
- Diabetes Mellitus, Type 2, Obesity
- Interventions
- Semaglutide, Insuline glargine U100 (reduced), Insuline glargine U100 (titrated)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 573 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 145
- States / cities
- Sheffield, Alabama • Glendale, Arizona • Mesa, Arizona + 113 more
- Conditions
- Poor Glycemic Control
- Interventions
- Metformin, Glargine insulin, Glulisine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Diabetes, Surgery
- Interventions
- Lantus, Insulin
- Drug · Other
- Lead sponsor
- Tamra Dukatz
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 2
- States / cities
- Royal Oak, Michigan • Troy, Michigan
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Human Insulin Inhalation Powder, Insulin Glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 6
- States / cities
- Greenbrae, California • Topeka, Kansas • Toms River, New Jersey + 3 more
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- Glulisine (Apidra)
- Drug
- Lead sponsor
- Carl T. Hayden VA Medical Center
- Federal
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin lispro, Glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Concord, California • Fresno, California + 30 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin Glargine, LY2189265, Insulin Lispro
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 884 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 36
- States / cities
- Concord, California • La Mesa, California • Lancaster, California + 33 more
- Conditions
- Type 2 Diabetes
- Interventions
- Insulin glargine/lixisenatide Fixed Ratio Combination, Insulin glargine (HOE901), Lixisenatide (AVE0010), Metformin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 118
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Little Rock, Arkansas + 98 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- SAR342434, Humalog, insulin glargine HOE901
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 505 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 51
- States / cities
- Foley, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 45 more